Prime Medicine: Buy Rating on Prime Editing Platform Targeting High-Value Liver and Lung Genetic Diseases, Led by PM577 in Wilson’s Disease

Prime Medicine, Inc. (PRME) has received a new Buy rating, initiated by LifeSci Capital analyst, Cory Jubinville, PhD.

Cory Jubinville, PhD has given his Buy rating due to a combination of factors that, in his view, position Prime Medicine for attractive risk‑reward. He highlights that Prime has deliberately reshaped its pipeline around high‑value, genetically well‑defined liver and lung diseases such as Wilson’s disease, AAT deficiency, and cystic fibrosis, where there is substantial unmet need and clear biological targets. The company’s prime editing platform is seen as a key differentiator versus both traditional AAV gene therapy and first‑generation CRISPR approaches, because it aims to durably repair causative mutations at their native locus and can be designed in a mutation‑agnostic or hotspot‑focused manner, potentially expanding the addressable patient population.

Jubinville also emphasizes that the lead program, PM577 in Wilson’s disease, could offer a more physiologic and potentially safer solution than chronic copper chelation, which is expensive, imperfect, and associated with early neurologic worsening in a meaningful subset of patients. By restoring native copper excretion rather than relying on lifelong chelators that rapidly strip copper from the body, PM577 may address both efficacy and safety limitations of the current standard of care and create a compelling value proposition in a market where drug spending is already high. While he acknowledges the company’s sizable cash burn and a limited cash runway, he appears to believe that the clinical and commercial upside of these prime editing programs, if successful, more than compensates for the financing and execution risks, supporting his Outperform/Buy view on the stock.